Xiaoyin Bai

Dr. Xiaoyin Bai

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2024 in Chinese Medical Journal
Verified
Journal Article
Open access
ZYZiqing Yu
Ziqing Yu
GRGechong Ruan
Gechong Ruan
XBXiaoyin Bai
Xiaoyin Bai
YSYinghao Sun
Yinghao Sun
HYHong Yang
Hong Yang
JQJiaming Qian
Jiaming Qian
Background: Inflammatory bowel disease (IBD) imposes a significant economic and social burden in China. We aim to assess the epidemiological trends of IBD in China, and to predict the burden in the near future. Methods: The incidence, mortality, prevalence, and disability-adjusted life year (DALYs) of IBD from 1990 to 2021 were obtained from Global Burden of Disease Study 2021. Estimated annual percentage change (EAPC), average annual percent change, total percent change, and age-period-cohort model were used to access trends. Bayesian age–period–cohort model was utilized to predict the risk of incidence and mortality. Results: In 2021, IBD affected 168,077 people in China, with 24,941 new cases and 5640 deaths. The age-standardized rate (ASR) of incidence and death was 1.4 and 0.3, respectively. The incidence and prevalence in China were lower than the global and high socio-demographic index (SDI) regions, but the ASR of incidence and prevalence (EAPC: 2.93 and 2.54, respectively) had rapidly increased from 1990 to 2021. The ASR of death and DALYs had significantly decreased (EAPC: −3.05 and −2.93, respectively). Middle-aged and elderly populations faced a severe burden of incidence and prevalence, while the elderly population faced a severe mortality burden. It is projected that by 2035, the ASR of incidence will continue to rise, whereas the death rate will continue to decline. Conclusions: The burden of IBD in China is serious and increasingly severe. Establishing a comprehensive disease management system in China will help better control the medical burden of IBD.

11 January 2025 in Gastroenterology Report
Verified
Journal Article
Open access
GRGechong Ruan
Gechong Ruan
YSYinghao Sun
Yinghao Sun
ZYZiqing Yu
Ziqing Yu
XBXiaoyin Bai
Xiaoyin Bai
HYHong Yang
Hong Yang
JQJiaming Qian
Jiaming Qian
Background: Inflammatory bowel disease (IBD) imposes a significant economic and social burden. We aimed to assess the burden of IBD globally, regionally, and nationally. Methods: The incidence, mortality, prevalence, and disability-adjusted life year were obtained from Global Burden of Disease 2021. Estimated annual percentage change, average annual percent change, and age-period-cohort model were used to access trends. Associations between age-standardized rate (ASR) and socio-demographic index were explored. Predictions were made using Bayesian age-period-cohort model and Nordpred. Results: In 2021, IBD affected 3.8 million people, with ASR of incidence and death of 4.4 and 0.5. The global ASR of incidence increased from 1990 to 2021, while ASR of death, prevalence, and disability-adjusted life year decreased. The age-standardized death rate (ASDR) did not show a significant increase from 2019 to 2021 in most regions and countries. High-incidence regions, such as Western Europe, continued to face significant burdens. East Asian, especially China, was experiencing a sharp increase in incidence. ASR of incidence and death increased with rising socio-demographic index. By 2035, the ASR of incidence and death of IBD will gradually decline. Conclusion: The global burden of IBD remains severe with changing epidemiological trends. Reducing the burden requires changes in public health policies, disease prevention, and healthcare services.

15 June 2022 in Hepatology International
Verified
Journal Article
Closed access
PDF file
JMJiarui Mi
Jiarui Mi
LJLingjuan Jiang
Lingjuan Jiang
ZLZhengye Liu
Zhengye Liu
XWXia Wu
Xia Wu
NZNan Zhao
Nan Zhao
XBXiaoyin Bai
Xiaoyin Bai

10 October 2022 in Frontiers in Nutrition
Verified
Journal Article
Open access
JMJiarui Mi
Jiarui Mi
ZLZhengye Liu
Zhengye Liu
LJLingjuan Jiang
Lingjuan Jiang
MLMeizi Li
Meizi Li
XWXia Wu
Xia Wu
YFYunlu Feng
Yunlu Feng
Background: There is very limited evidence on the causal effects of blood metabolites on pancreatitis risks. To reveal the causal associations between plasma metabolites and pancreatitis risks, we performed two-sample Mendelian randomization (MR) and Bayesian model averaging (MR-BMA) analyses in European ancestry.Methods: The summary-level statistics from two genome-wide association studies with 249 and 123 metabolic traits derived from two separate cohorts involving ~115,000 (UK Biobank) and ~25,000 individuals from European ancestry were used for the analyses. The summary statistics of four pancreatitis datasets from FinnGen R5 and two pancreatitis datasets from UK Biobank were exploited as the outcome. We first performed univariable MR analysis with different metabolic GWAS data on multiple pancreatitis datasets to demonstrate the association pattern among different metabolites categories. Next, we exploited the MR-BMA method to pinpoint the dominating factors on the increased risk of pancreatitis.Results: In the primary analysis with 249 traits, we found that plasma triglycerides were positively associated with pancreatitis risk. Intriguingly, a large number of traits associated with saturation or unsaturation of fatty acids also demonstrated causal associations. The replication study analyzing 123 metabolic traits suggested that bisallylic groups levels and omega-3 fatty acids were inversely correlated with pancreatitis risk. MR-BMA analyses indicated that the ratio of triglycerides to total lipid in various HDL particles played leading roles in pancreatitis susceptibility. In addition, the degree of unsaturation, the ratio of polyunsaturated fatty acids to monounsaturated fatty acids and the level of monounsaturated fatty acids showed causal associations with either decreased or increased pancreatitis susceptibility.Conclusions: Our MR study provided an atlas of causal associations of genetically predicted blood metabolites on pancreatitis, and offered genetic insights showing intervention in triglycerides and the supplementation of unsaturated fatty acids are potential strategies in the primary prevention of pancreatitis.

24 July 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
ZLZhaoshi Liu
Zhaoshi Liu
HTHao Tang
Hao Tang
HLHaozheng Liang
Haozheng Liang
XBXiaoyin Bai
Xiaoyin Bai
HZHuimin Zhang
Huimin Zhang
JQJiaming Qian
Jiaming Qian
Background: Clinical data on the correlation of dyslipidaemia with the long-term outcomes of ulcerative colitis (UC) are limited. This study aimed to evaluate the impact of lipid levels on disease activity and prognosis in UC. Methods: The retrospective data of UC patients who had detailed lipid profiles were collected from January 2003 to September 2020. All patients were followed-up to 30 September 2021. The long-term outcomes were UC-related surgery and tumorigenesis. Results: In total, 497 patients were included in the analysis. Compared to patients with normal lipid levels, those with dyslipidaemia commonly presented with more serious disease activity. Low high-density lipoprotein cholesterol (p < 0.05) levels were associated with higher risks of severe disease activity in UC. Regarding the long-term outcomes, patients with persistent dyslipidaemia were at higher risks of UC-related surgery (HR: 3.27, 95% CI: 1.86–5.75, p < 0.001) and tumorigenesis (HR: 7.92, 95% CI: 3.97–15.78, p < 0.001) and had shorter surgery- and tumour-free survival (p < 0.001) than patients with transient dyslipidaemia and normal lipid levels. Low levels of high-density lipoprotein cholesterol (p < 0.001) and apolipoprotein A1 (p < 0.05) were associated with higher risks of surgery and tumorigenesis. Conclusion: Persistent dyslipidaemia was associated with a higher risk of serious disease activity and worse long-term outcomes among patients with UC. Lipid patterns should be assessed to improve the management of high-risk patients with UC in the early phase.

14 August 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
WWWei Wei
Wei Wei
PYPengguang Yan
Pengguang Yan
FWFang Wang
Fang Wang
XBXiaoyin Bai
Xiaoyin Bai
JWJing Wang
Jing Wang
KYKang Yu
Kang Yu
(1) Background: The Global Leadership Initiative on Malnutrition (GLIM) was published in 2019, and its application has been explored in several diseases. However, the data on malnutrition based on the GLIM in ulcerative colitis (UC) patients are sparse. (2) Methods: This single-center, retrospective cohort study included 605 hospitalized UC patients. Demographics and clinical data were collected from electronic medical records. Nutritional Risk Screening 2002 (NRS 2002) was used as a screening tool, and malnutrition was diagnosed according to the GLIM criteria. The skeletal muscle area of the third lumber cross-section in abdominal computed tomography was used to evaluate muscle mass within one week before or after admission. (3) Results: The prevalence of malnutrition was 64.1% in this cohort, and the prevalences were 34.2, 57.7, and 86.7% in UC patients with mild, moderate, and severe disease activity, respectively. Malnourished patients tended to need surgical treatment (p = 0.080) and had a 2.4 times greater risk of opportunistic infection. The multivariate logistic regression analysis showed that UC patients with malnutrition had a 1.7-fold increased risk of readmission. (4) Conclusions: Nutritional problems deserve more attention in hospitalized UC patients. Malnutrition identified through the GLIM criteria was associated with opportunistic infection, tended to be associated with surgical treatment, and showed a prognosis value for readmission.